Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host
Conference Call on November 12
POINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Transcept
Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company
focused on the development and commercialization of proprietary products that
address important therapeutic needs in the field of neuroscience, today
announced it will host a webcast and teleconference with management to discuss
third quarter 2009 financial results on Thursday, November 12, 2009, at 5:00
p.m. Eastern Standard Time. Financial results for the third quarter ended
September 30, 2009 will be released earlier that afternoon.
Conference Call Information
Date: Thursday, November 12, 2009
Time: 5:00 p.m. EST
Dial-in (U.S.): 877-874-1589
Dial-in (International): 719-325-4805
A simultaneous webcast of the conference call will be available on the
Investors section of the Transcept website at www.transcept.com. A replay of
this webcast will be available on the website beginning shortly after the
conclusion of the call through November 27, 2009.
A telephone replay of the conference call will be available beginning shortly
after the conclusion of the call through November 27, 2009. The replay
telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International),
Replay Passcode: 2918743.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of proprietary products that address
important therapeutic needs in neuroscience. The most advanced Transcept
product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for
which a New Drug Application (NDA) was submitted to the U.S. Food and Drug
Administration (FDA) in September 2008 seeking approval as a prescription
sleep aid for use in the middle of the night at the time a patient awakens and
has difficulty returning to sleep. In October 2009, Transcept received a
Complete Response Letter from the FDA on the Intermezzo® NDA and is working to
respond to issues raised in the letter. Transcept and Purdue Pharmaceutical
Products, L.P. have entered into a collaboration agreement for the development
and commercialization of Intermezzo® in the United States. For further
information, please visit the company's website at: www.transcept.com.
Contacts:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director of Corporate Communications
(510) 215-3567
gmann@transcept.com
SOURCE Transcept Pharmaceuticals, Inc.
Greg Mann, Director of Corporate Communications of Transcept Pharmaceuticals,
Inc., +1-510-215-3567, gmann@transcept.com
